These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27372548)

  • 1. Practical Estimation of Amorphous Solubility Enhancement Using Thermoanalytical Data: Determination of the Amorphous/Crystalline Solubility Ratio for Pure Indomethacin and Felodipine.
    Skrdla PJ; Floyd PD; Dell'orco PC
    J Pharm Sci; 2016 Sep; 105(9):2625-2630. PubMed ID: 27372548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Jan; 555():100-108. PubMed ID: 30448307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Method of Constructing a Drug-Polymer Temperature-Composition Phase Diagram Using Hot-Melt Extrusion.
    Tian Y; Jones DS; Donnelly C; Brannigan T; Li S; Andrews GP
    Mol Pharm; 2018 Apr; 15(4):1379-1391. PubMed ID: 29205040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of Different Methods for the Prediction of Drug-Polymer Solubility.
    Knopp MM; Tajber L; Tian Y; Olesen NE; Jones DS; Kozyra A; Löbmann K; Paluch K; Brennan CM; Holm R; Healy AM; Andrews GP; Rades T
    Mol Pharm; 2015 Sep; 12(9):3408-19. PubMed ID: 26214347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution and precipitation behavior of amorphous solid dispersions.
    Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS
    J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Aug; 567():118465. PubMed ID: 31279056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility.
    Marsac PJ; Shamblin SL; Taylor LS
    Pharm Res; 2006 Oct; 23(10):2417-26. PubMed ID: 16933098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions.
    Tian Y; Booth J; Meehan E; Jones DS; Li S; Andrews GP
    Mol Pharm; 2013 Jan; 10(1):236-48. PubMed ID: 23110477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation into the role of polymeric carriers on crystal growth within amorphous solid dispersion systems.
    Tian Y; Jones DS; Andrews GP
    Mol Pharm; 2015 Apr; 12(4):1180-92. PubMed ID: 25692314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamic phase behaviour of indomethacin/PLGA formulations.
    Prudic A; Lesniak AK; Ji Y; Sadowski G
    Eur J Pharm Biopharm; 2015 Jun; 93():88-94. PubMed ID: 25791211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S; Mao C; Williams RO; Yang CY
    J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the behavior of amorphous pharmaceutical systems during dissolution.
    Alonzo DE; Zhang GG; Zhou D; Gao Y; Taylor LS
    Pharm Res; 2010 Apr; 27(4):608-18. PubMed ID: 20151181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuances in the Calculation of Amorphous Solubility Enhancement Ratio.
    Manchanda A; Kleppe MS; Bogner RH
    J Pharm Sci; 2019 Nov; 108(11):3560-3574. PubMed ID: 31271772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water.
    Marsac PJ; Konno H; Rumondor AC; Taylor LS
    Pharm Res; 2008 Mar; 25(3):647-56. PubMed ID: 17846870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of Crystalline and Amorphous Surface Regions Using Time-of-Flight Secondary-Ion Mass Spectrometry (ToF-SIMS): Application to Pharmaceutical Materials.
    Iuraş A; Scurr DJ; Boissier C; Nicholas ML; Roberts CJ; Alexander MR
    Anal Chem; 2016 Apr; 88(7):3481-7. PubMed ID: 26916467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative model to evaluate solubility relationship of polymorphs from their thermal properties.
    Mao C; Pinal R; Morris KR
    Pharm Res; 2005 Jul; 22(7):1149-57. PubMed ID: 16028016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.